Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 16/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 13/20 | 1.00 |
| ▸ | HPGD | P15428 | 9/20 | 1.00 |
| ▸ | HTT | P42858 | 8/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 1.00 |
| ▸ | ATM | Q13315 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 0.95 |
| ▸ | GAA | P10253 | 3/20 | 0.80 |
| ▸ | POLB | P06746 | 2/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | IDH1 | O75874 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KHK | P50053 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17344002 | 0.79 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHTTNPSR1 | |
| SCHEMBL6255135 | 0.74 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHTTNPSR1 | |
| SCHEMBL1320500 | 0.74 | ALDH1A1 (0.66) | ALDH1A1KDM4EHPGDHTTNPSR1 | |
| SCHEMBL2614845 | 0.74 | ALDH1A1 (0.66) | ALDH1A1KDM4EHPGDHTTNPSR1 | |
| SCHEMBL14251704 | 0.73 | IDH1 (1.00) | ALDH1A1KDM4EHPGDHTTNPSR1 | |
| SCHEMBL14250219 | 0.71 | HTT (0.67) | ALDH1A1KDM4EHPGDHTTNPSR1 | |
| SCHEMBL15877665 | 0.69 | IDH1 (1.00) | ALDH1A1KDM4EHPGDHTTNPSR1 | |
| SCHEMBL11753128 | 0.67 | ALDH1A1 (0.76) | ALDH1A1KDM4EHPGDHTTNPSR1 | |
| SCHEMBL23570923 | 0.67 | ALDH1A1 (0.58) | ALDH1A1KDM4EHPGDHTTNPSR1 | |
| SCHEMBL4821841 | 0.65 | KDM4E (0.78) | ALDH1A1KDM4EHPGDHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220313650-A1 | METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS | THE BROAD INSTITUTE, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220211658-A1 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH SLEEP SPINDLE DEFICITS | THE BROAD INSTITUTE, INC. (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220211658-A1 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH SLEEP SPINDLE DEFICITS | THE BROAD INSTITUTE, INC. (US) | 2022-07-07 | — | — | US | disclosed |
| US-10059671-B2 | Positive allosteric modulators of mGluR3 | PREXTON THERAPEUTICS SA (CH) | 2018-08-28 | — | — | US | disclosed |
| US-20150361046-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR3 | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | disclosed |
| US-20150361046-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR3 | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | disclosed |
| US-20150361046-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR3 | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | disclosed |
| EP-2951157-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR3 | Merck Patent GmbH (DE) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014117919-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR3 | MERCK PATENT GMBH (DE) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014117919-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR3 | MERCK PATENT GMBH (DE) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220313650-A1 | METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS | GRIN2A, GRIN2B, GRM2 | ALDH1A1 1408/4885KDM4E 2165/4885HPGD 2482/4885 |
| US-20150361046-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR3 | GRM3, GRM1, GRM4 | ALDH1A1 4723/4885KDM4E 1126/4885HPGD 3834/4885 |
| US-10059671-B2 | Positive allosteric modulators of mGluR3 | GRM3, GRM1, GRM4 | ALDH1A1 4723/4885KDM4E 1126/4885HPGD 3834/4885 |
| US-20220211658-A1 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH SLEEP SPINDLE DEFICITS | HCRTR2, GRIN2A, GRM2 | ALDH1A1 1485/4885KDM4E 1435/4885HPGD 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.